2TABLE 2.1 Prevention in T1DTABLE 2.2 Current TrialNet studies. (Source: www.trialnet.net)TABLE 2.3 Immunotherapy trials that are awaiting, or currently recruiting, p...
3 Chapter 4TABLE 4.1 Types of diabetes.TABLE 4.2 Overview of secondary diabetes due to pancreatic disease and hormo...TABLE 4.3 Clinical features of T1DM, T2DM and CFRD. Adapted from [49].
4 Chapter 6TABLE 6.1 Options for GDM screening and diagnosis.TABLE 6.2 Guidelines for gestational weight gain based on prepregnancy BMI.
5 Chapter 8TABLE 8.1 International consensus on use of CGM.TABLE 8.2 Measures used to quantify glycemic variation (modified from [64]).
6 Chapter 9TABLE 9.1 Continuous glucose monitoring (CGM) impact in diabetes (randomized...TABLE 9.2 Pivotal studies of closed loop system.TABLE 9.3 Brief synopsis of current and future technologies in closed loop.
7 Chapter 11TABLE 11.1 Direct and indirect effects of metformin therapy.TABLE 11.2 Molecular targets of PPARγ and PPAR α action.
8 Chapter 12TABLE 12.1 GLP‐1 RAs: effects on glucose and weight in head‐to‐head trials.
9 Chapter 14TABLE 14.1 Patient characteristics that might affect prescribing.
10 Chapter 15TABLE 15.1
11 Chapter 19TABLE 19.1 Class I indications for myocardial revascularization in stable i...
12 Chapter 20TABLE 20.1 Trial design, patient characteristics.TABLE 20.2 APACHE scores and mortality data.TABLE 20.3 Hypoglycemia data.
13 Chapter 21TABLE 21.1 Ocular complications of diabetes and treatment options.TABLE 21.2 Initial screening recommendations for DR in patients with diabet...TABLE 21.3 International classification of diabetic retinopathy and diabeti...
14 Chapter 22TABLE 22.1 Treatment strategies for patients with gastroparesis (reproduced...
List of Illustrations
1 Chapter 1FIG 1.1 Histogram with superimposed composite and component curves to descri...FIG 1.2 Postprandial and fasting glucose concentrations are determined by in...
2 Chapter 2FIG 2.1 Pathogenesis and natural history of Type 1 diabetes. Atkinson MA and...FIG 2.2 Strategies to preserve β‐cell mass in T1D. Modified from Reimann M, ...FIG 2.3 T1D clinical research over the past 10 year. Atkinson MA, Roep BO, P...
3 Chapter 4FIG 4.1 Proposed algorithm for screening and treatment of haemochromatosis i...
4 Chapter 6FIGURE 6.1 Key factors contributing to excessive fetal growth.
5 Chapter 7FIG 7.1 Typical patient glucose logbook with self‐reported data.FIG 7.2 Modal Day presentation of downloaded meter with SMBG data.FIG 7.3 Varying outputs from commercially available CGM devices.FIG 7.4 CGM device output as a Modal Day.FIG 7.5 Universal CGM output as ambulatory glucose profile (AGP). A. Subject...
6 Chapter 8FIG 8.1A Glycemic variation with frequent insulin supplements. 40‐year‐old w...FIG 8.1B Glycemic variation due to within day variation (WDV) from steroids....
7 Chapter 10FIG 10.1 Schematic representation of the relationship between caloric densit...
8 Chapter 11FIG 11.1 Hypothesized mechanism of action of metformin on hepatic glucose pr...FIG 11.2 Effects of metformin on fatty acid metabolism.FIG 11.3 Effects of thiazolidinediones.
9 Chapter 14FIG 14.1 Therapeutic classes clustered by therapeutic effect versus the leve...
10 Chapter 17FIG 17.1 Role of PCSK9 in hepatic uptake of LDL particles. Low density lipop...FIG 17.2 Metabolism of triglyceride‐rich lipoproteins (TGRL). The two princi...
11 Chapter 18FIG 18.1 Bariatric surgeries. (A) Laparoscopic adjustable gastric banding (G...
12 Chapter 19FIG 19.1 Algorithm to guide diagnosis and management.
13 Chapter 20FIG 20.1 Energy supply expressed as a percentage of estimated basal energy e...FIG 20.2 Energy supply versus insulin infusion rate in five studies.
14 Chapter 21FIG 21.1 Diabetic retinopathy and diabetic macular edema. A. Fundus photogra...
15 Chapter 22FIG 22.1 Assessment of gastric emptying by scintigraphy. Normally liquids ar...
Guide
5 Preface
8 Index
9 Wiley End User License Agreement
Pages
1 iii
2 iv
3 vii
4 viii
5 ix
6 x
7 1
8 3
9 4
10 5
11 6
12 7
13